CSPC's Research Results of Butylphthalide Published in JAMA Sub-Journal

July 17, 2023

On June 27, 2023, JAMA Neurology (IF=29.907; CAS quartile: Medicine Q1 Top), a top journal in the field of neuroscience, published CSPC's BAST research on butylphthalide products in full text online (Efficacy and Safety of Butylphthalide in Patients with Acute Ischemic Stroke: A Randomized Clinical Trial) According to the research results on patients with acute ischemic stroke receiving intravenous thrombolysis and/or intravascular therapy, butylphthalide can improve their 90-day good functional outcome compared with placebo. 

BAST research is the first international clinical trial of neuroprotective drugs with effective endpoints in combination with perfusion therapy. JAMA series journals belong to the journal series of the American Medical Association (AMA). It is one of the top four medical journals and also an international peer-reviewed medical academic journal. The publication of the research results further affirm the role of butylphthalide, a branded drug from China for the treatment of cerebrovascular diseases, in improving the clinical prognosis of patients treated with intravenous thrombolysis and/or endovascular therapy, which fully reflects the recognition of Chinese research by international peers, and at the same time makes contributions to the exploration and development of cerebrovascular diagnosis and treatment in the future.

Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |